Article
Argenx To Advance ARGX-119 To Registrational Trial For Congenital Myasthenic Syndromes
Neutral
0.0
−100 Bearish
0
+100 Bullish
(RTTNews) - argenx SE (ARGX) announced that it plans to advance ARGX-119—a first-in-class agonist antibody targeting muscle-specific kinase (MuSK)—to a registrational study in patients with congenital myasthenic syndromes, following topline data from its Phase 1b trial.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
NASDAQ Markets
Published
Jun 30, 2025 · 5:36 am
Article ID
12778650694624971277
Original URL
Open source
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This